Embrace The Digital Revolution, But On Your Own Terms, John Nosta Says

30 Oct 2018

• By David Filmore

Digital health and innovation strategist John Nosta talks about the need for medical technology companies to stay true to their technology roots and not get too attached to the "patient centricity" bandwagon. Also: innovating organically and "failing smart."

John Nosta, Nostalabs — John Nosta on the speaking circuit

Device companies are under pressure not only to be more of a solutions-provider and cost-saver to hospitals, but, increasingly, to establish more direct engagement with patients. With disruptive pressures from tech players like Apple and Google, and retail giants like Amazon and CVS, the push for medical device firms to engage patients more directly with the help of data analytics and digital tools is high. (Also see "Industry Is Falling Short In Digital Investments" - Medtech Insight, 24 September, 2018.)

MedTech Meeting

Nosta will offer a keynote address the MedTech Association's annual meeting in Syracuse, NY, on Nov. 14. The meeting runs Nov. 13-14.

But while there is no question the paradigm for health care is undergoing massive change, medtech firms shouldn't forget where...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

Ochsner Surgeon In ‘The Big Easy’ Eases Patient’s Pain With Skill And Virtual Reality

11 Jul 2025

• By Brian Bossetta

A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.

Execs On The Move: June 30–July 4, 2025

10 Jul 2025

• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

10 Jul 2025

• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.